Over the past three decades, the pharmaceutical development model has evolved continuously in an effort to improve both speed and cost efficiency. Today, the industry appears to be approaching another structural inflection point. Several forces are converging to intensify pressure on pharmaceutical companies to deliver new profitable therapies more efficiently than ever before: sustained pressure on pipelines due to patent expirations, increasing drug pricing scrutiny and rapid technology progress. Taken together, these pressures raise an important strategic question:
Is the current pharmaceutical model ready to respond to a rapidly changing technological, societal and geopolitical environment?
Through engaging with leaders in the industry, Oaklin has explored how the R&D model has evolved, the forces currently reshaping it, and what these trends mean for pharmaceutical companies defining and implementing the business model of the future. We explore this through the lens of 5 main areas undergoing rapid transformation: (1) digital drug discovery, (2) buying innovation, (3) clinical trials, (4) commercialisation and (5) manufacturing and supply chains.
